Belite Bio Q4 Earnings Call Highlights [Yahoo! Finance]
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: Yahoo! Finance
Belite Bio (NASDAQ:BLTE) used its fiscal fourth quarter and full-year 2025 earnings call to outline regulatory and commercialization plans for tinlarebant in Stargardt disease, provide updates across its clinical portfolio, and review a sharply expanded cash position following multiple financings. DRAGON phase III results and next clinical steps Management highlighted December's top-line readout from the Phase III pivotal DRAGON trial in Stargardt disease as a key milestone. According to the company, the study met its primary efficacy endpoint, showing a 36% reduction in the growth rate of atrophy lesion measured by definitely decreased autofluorescence (DDAF) ? The Head Fake: Buying the Chinese Stocks Post-Ruling Dip The company also provided enrollment updates on two late-stage studies: DRAGON II : Belite Bio said it reached its target of 60 subjects in January. As of Feb. 27, enrollment stood at 72 subjects, and management expects final enrollment of 72 to 75 participant
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Belite Bio price target raised to $266 from $200 at Cantor Fitzgerald [Yahoo! Finance]Yahoo! Finance
- Belite Bio (BLTE) was given a new $217.00 price target by Needham & Company LLC.MarketBeat
- Belite Bio (BLTE) had its price target raised by HC Wainwright from $185.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
- Belite Bio (BLTE) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Belite Bio (BLTE) had its "buy" rating reaffirmed by Benchmark Co..MarketBeat
BLTE
Earnings
- 3/2/26 - Beat
BLTE
Sec Filings
- 3/2/26 - Form 6-K
- 2/17/26 - Form SCHEDULE
- 1/30/26 - Form S-8
- BLTE's page on the SEC website